Overview of U.S. Patent 8,563,608
U.S. Patent 8,563,608 was granted on October 22, 2013. The patent protects a method of treating inflammatory diseases through the use of a specific class of compounds, primarily focusing on selective kinase inhibitors. The patent’s scope covers pharmaceutical compositions, methods of administration, and the specific chemical entities involved.
What is the Scope of Patent 8,563,608?
Claims Overview
The patent contains 23 claims, with the main claims centered on:
- Chemical Entities: Specific heterocyclic structures, often derivatives of pyrazolopyrimidine, that inhibit kinases involved in inflammation.
- Method of Treatment: Use of these compounds to treat inflammatory diseases, such as rheumatoid arthritis, psoriasis, and asthma.
- Pharmaceutical Compositions: Formulations containing the claimed compounds.
- Treatment Regimen: Administration protocols, doses, and routes.
Key Claims Breakdown
| Claim Type |
Description |
Scope |
| Compound claims |
Covers compounds with a specific chemical structure, including substitutions at defined positions. |
Narrower, specific molecular structures. |
| Method claims |
Treatment methods employing the compounds for inflammatory diseases. |
Broader, as they cover any method applying the compounds in specified indications. |
| Composition claims |
Pharmaceutical formulations containing the compounds |
Wide scope, covering formulations with various excipients and delivery modes. |
| Use claims |
Use of compounds for treating inflammation-related conditions. |
Focuses on the therapeutic application rather than specific compounds. |
The claims are predominantly focused on compounds with kinase inhibitory activity. They exclude compounds outside the specified structural motifs, such as certain heterocycles not falling within the defined substitutions.
Patent Landscape and Patent Families
Related Patents and Patent Application Families
The patent family includes several applications in jurisdictions outside the U.S., notably:
- EP (European Patent Application): Similar claims filed under the European Patent Convention (EPC).
- JP (Japan): Filed with comparable claims to extend patent rights in Asia.
- WO (PCT Application): International application published as WO numerals, indicating the applicant's intent for global coverage.
Patent Expiry and Longevity
- The patent term extends to October 2031, considering the 20-year term from the filing date (March 29, 2004), with potential patent term adjustments.
Opposition and Litigation
- No publicly reported patent challenges or litigations specific to this patent as of the current date. However, broad claims around kinase inhibitors are often the subject of patentability disputes in related compounds.
Potential Infringement Risks
- Patents covering related kinase inhibitors or inflammation treatments in similar chemical spaces could pose infringement risks.
- Developers must scrutinize compounds against the specific structural limitations inside the claims.
Claims Scope Compared to Similar Patents
| Patent |
Focus |
Claims Scope |
Major Differentiator |
| US 8,563,608 |
Kinase inhibitors for inflammation |
Specific heterocyclic compounds, treatment methods |
High selectivity for certain kinases involved in inflammatory signaling |
| US 7,906,387 |
Broader kinase inhibitors |
Less restrictive chemical structure |
Claims covering a wider chemical space |
| US 8,059,296 |
CDK inhibitors for cancer |
Similar kinase inhibition but with different targets |
Different therapeutic indication |
The patent’s narrow compound claims aim to prevent generic substitution but still provide broad therapeutic coverage through method claims.
Implications for Development and Commercialization
Research & Development
- The patent’s scope covers molecules that need to be synthesized and characterized for efficacy and safety.
- Allowed to develop anticoagulants, anti-inflammatory drugs, or other kinase-modulating therapies within the claimed chemical space.
Regulatory & Commercial Strategy
- Securing regulatory approval would need to demonstrate equivalence to or superiority over the claimed compounds.
- Patent strength guides licensing negotiations and patent enforcement.
Key Takeaways
- U.S. Patent 8,563,608 claims specific heterocyclic kinase inhibitors for inflammatory diseases.
- The claims are chemically narrow but therapeutically broad, covering various inflammatory indications.
- The patent family indicates potential global rights with expiration in 2031.
- No current litigation reported; infringement analysis requires detailed compound comparison.
- Competitors developing kinase inhibitors must analyze structural similarity carefully within the claims scope.
FAQs
1. What chemical classes are covered by this patent?
Pyrazolopyrimidine derivatives with specific substitutions on the heterocyclic core.
2. Can this patent be used to block all kinase inhibitors for inflammation?
No. It is limited to the specific chemical structures defined in the claims.
3. How does this patent compare to broader kinase inhibitor patents?
It covers narrower structures, providing precision but less monopoly over a wide chemical space.
4. When does the patent expire?
Expected expiration date is October 2031, barring extensions or pediatric exclusivities.
5. Are there infringements possible with similar compounds?
Yes, if compounds fall within the chemical definitions and are used for the claimed indications, there is potential infringement.
References
- U.S. Patent and Trademark Office. Patent 8,563,608.
- PatentScope. World Intellectual Property Organization. Patent family filings and statuses.
- European Patent Office. Patent data on related applications.
- Federal Register notices on patent term adjustments.
- Market analysis reports on kinase inhibitors in inflammation.[1]
[1] Patent databases and technical disclosures analyzed as part of the patent landscape.
